Rogers Corp

ROGERS, Conn.-- Rogers Corp.' s shares fell about 4 percent in after-hours trading Tuesday after the company lowered its second-quarter earnings forecast and unveiled major cost-cutting measures. The company also said Tuesday that it expects to earn between 32 and 43 cents per share for its second quarter, down from its earlier forecast of 45 to 56 cents per share.

*Risks include high valuation, competitive threats By Ransdell Pierson. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.

ZURICH, May 7- Swiss stocks were expected to open little changed on Tuesday as other European share markets were indicated slightly firmer but Asian stocks were capped by weak global growth data. The Swiss blue-chip SMI was seen flat at 7,928 points, according to premarket indications from bank Julius Baer.

The FDA issued a warning on its website saying that some third-party publications, health information systems and websites were incorrectly using a truncated version of Kadcyla's generic name.

The U.S. Food and Drug Administration issued a warning on its website saying that some third-party publications, health information systems and websites were incorrectly using a truncated version of Kadcyla's generic name.

May 6- Roche Holding AG:. *US FDA warns use of short version of Roche Holding's breast cancer. *FDA says dosing, treatment schedules for Roche's Kadcyla and Herceptin are.

*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.

CHICAGO, May 1- The first-ever drug designed to treat social impairments associated with autism failed to show a benefit in a midstage trial, representing a blow to families and to privately held drugmaker Seaside Therapeutics.

CHICAGO, May 1- The first-ever drug designed to treat social impairments associated with autism failed to show a benefit in a midstage trial, representing a blow to families and to privately held drugmaker Seaside Therapeutics.

CHICAGO, May 1- The first-ever drug designed to treat social impairments associated with autism failed to show a benefit in a midstage trial, representing a blow to families and to privately held drugmaker Seaside Therapeutics.

*EU court stops EMA releasing AbbVie, InterMune drug data. LONDON, April 30- The head of Europe's medicines regulator is digging in for a fight over data transparency after being stopped from releasing information on drugs from two U.S. companies by a court ruling.

The European Medicines Agency said on Friday its experts had also backed MAC1, a tissue-engineered medicine for cartilage defects from Sanofi's Genzyme unit, and Spedra, a new erectile dysfunction drug from Vivus.

LONDON, April 26- European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas. The European Medicines Agency said on Friday its experts had also backed MAC1, a tissue-engineered medicine for cartilage defects from Sanofi, and Spedra, a new erectile dysfunction drug from Vivus.

ZURICH, April 26- Swiss stocks were expected to tick lower at the open of trading on Friday as investors trim positions following a five session rally. Swiss hearing aid maker Sonova.

ZURICH, April 26- The following are some of the main factors expected to affect Swiss stocks on Friday:. Citigroup Inc has hired two former UBS AG base metals executives to its growing metals trading desk as part of the U.S. bank's expansion of its commodities business, the bank said on Thursday.